Condition
Node; Prostate
Total Trials
2
Recruiting
0
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
P 2 (1)
Trial Status
Suspended1
Active Not Recruiting1
Clinical Trials (2)
Showing 2 of 2 trials
NCT03795207Phase 2Active Not RecruitingPrimary
Prostate Cancer With OligometaSTatic Relapse: Combining Stereotactic Ablative Radiotherapy and Durvalumab (MEDI4736)
NCT05820633Not ApplicableSuspended
Pelvic Nodes Ultra-Hypo vs Conventionally Fractionated IMRT With HDR Boost in Prostate Cancer.
Showing all 2 trials